News - Merck & Co


Current filters:

Merck & Co

Popular Filters

51 to 75 of 283 results

Merck & Co joins string of “restructurers,” cutting 8,500 jobs

Merck & Co joins string of “restructurers,” cutting 8,500 jobs


US pharma giant Merck & Co is the latest of a flood of leading drugmakers to announce restructuring plans,…

FinancialManagementMerck & CoPharmaceuticalResearch

Aspen Pharma reports rise in profits from new product launches


South Africa's leading drugmaker Aspen Pharmacare (APN: SJ) has released financial results which show…

ArixtraAspen PharmacareFinancialFraxiparineGlaxoSmithKlineMerck & CoPharmaceuticalRest of the World

AstraZeneca gains rights to Merck ovarian cancer candidate


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

First biosimilar monoclonal antibody approved in Europe


US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Depomed expands geographic scope of metformin deal with Merck


USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

Merck & Co to co-promote diabetes agent ipragliflozin in Japan


Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

BPH drug doesn't increase risk of death, but does save men from prostate cancer


A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

Avanir to promote Merck's diabetes drug Januvia


US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug…

Avanir PharmaceuticalsDiabetesJanuviaMarkets & MarketingMerck & CoNorth AmericaPharmaceutical

Generic Temodar launches in USA


Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

Bionomics in $172 million pain treatment deal with US pharma giant


Australian biotech firm Bionomics (ASX: BNO) has entered an agreement with US pharma giant Merck & Co…

BionomicsBiotechnologyLicensingMerck & CoNeurologicalPharmaceuticalResearch

Merck & Co records loss in 2nd quarter as Singulair drops 80%


US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

Slow uptake of HPV vaccine in USA "risks health of next generation"


US human papillomavirus (HPV) vaccination rates in girls aged 13-17 years failed to increase between…

CervarixGardasilGlaxoSmithKlineHealthcareMerck & CoNorth AmericaPharmaceuticalVaccines

Merck & Co's NDA for vorapaxar accepted for standard review by US FDA


US pharma giant Merck & Co (NYSE: MRK) has said the New Drug Application (NDA) for its once-troubled…

Cardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationvorapaxar

New Zealand consults on Victrelis listing and some Pegasys amendments


New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children


In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

First IQWiG assessment of the established drug market finds advantage for Januvia


There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

Melanoma market set to grow to more than $2.8 billion by 2021


The branded melanoma drug market is set to grow to more than $2.8 billion across the USA and major European…

Bristol-Myers SquibblambrolizumabMarkets & MarketingMerck & CoOncologyPharmaceuticalYervoy

Cardiome signs deal with AOP Orphan to market CAF drug Brinavess


Canada-based Cardiome Pharma (TSX: COM) has signed an agreement with Austrian firm AOP Orphan Pharmaceuticals…

AOP OrphanBrinavessCardio-vascularCardiome PharmaMerck & CoPharmaceutical

US FDA delays Merck & Co's insomnia drug suvorexant, issuing CRL


There was disappointment for US drug giant Merck & Co (NYSE: MRK), which said that it has received a…

Merck & CoNeurologicalNorth AmericaPharmaceuticalRegulationsuvorexant

51 to 75 of 283 results

Back to top